Clinical evidence Table 1 provides a consolidated overview of the key clinical trials evaluating incretin-based therapies in MASLD/MASH, including their study populations, dosing regimens, and primary histologic or metabolic outcomes
Blood Pressure Reduction (SURMOUNT-1) Krumholz HM, de Lemos JA, Sattar N, et al
Fine for larger doses, but problematic if you need 100 mcg, because 100 mcg would be just 0.02 mL, or 2 units on the syringe
References and Further Reading: Tongta, S., Sungkaworn, T., & Pathomthongtaweechai, N
Liraglutide forms noncovalent bonds to albumin (molecular weight, ~67 kDa) through a C 16 fatty acid chain [14]